Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.
about
The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-LifeInfluence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide.Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.
P2860
Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Population pharmacodynamic mod ...... ng anti-Xa levels as endpoint.
@en
Population pharmacodynamic mod ...... ng anti-Xa levels as endpoint.
@nl
type
label
Population pharmacodynamic mod ...... ng anti-Xa levels as endpoint.
@en
Population pharmacodynamic mod ...... ng anti-Xa levels as endpoint.
@nl
prefLabel
Population pharmacodynamic mod ...... ng anti-Xa levels as endpoint.
@en
Population pharmacodynamic mod ...... ng anti-Xa levels as endpoint.
@nl
P2093
P2860
P1476
Population pharmacodynamic mod ...... ng anti-Xa levels as endpoint.
@en
P2093
Bert van Ramshorst
Christian M Hackeng
Eric P A van Dongen
Esther J H Janssen
Jeroen Diepstraten
René J Wiezer
P2860
P2888
P356
10.1007/S00228-014-1760-4
P577
2014-10-12T00:00:00Z